Form 8-K - Current report:
SEC Accession No. 0001193125-24-002892
Filing Date
2024-01-05
Accepted
2024-01-05 08:02:02
Documents
18
Period of Report
2024-01-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d110504d8k.htm   iXBRL 8-K 33664
2 EX-1.1 d110504dex11.htm EX-1.1 220226
3 EX-5.1 d110504dex51.htm EX-5.1 10141
4 EX-99.1 d110504dex991.htm EX-99.1 9388
8 GRAPHIC g110504g0105100056224.jpg GRAPHIC 3002
9 GRAPHIC g110504g0105110044970.jpg GRAPHIC 1584
10 GRAPHIC g110504g0105110045220.jpg GRAPHIC 6662
  Complete submission text file 0001193125-24-002892.txt   481433

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA dyn-20240104.xsd EX-101.SCH 2847
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE dyn-20240104_lab.xml EX-101.LAB 17978
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dyn-20240104_pre.xml EX-101.PRE 11257
12 EXTRACTED XBRL INSTANCE DOCUMENT d110504d8k_htm.xml XML 3341
Mailing Address 1560 TRAPELO ROAD WALTHAM MA 02451
Business Address 1560 TRAPELO ROAD WALTHAM MA 02451 (781) 786-8230
Dyne Therapeutics, Inc. (Filer) CIK: 0001818794 (see all company filings)

EIN.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39509 | Film No.: 24514471
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)